EliLillyand Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...
She names EliLilly (LLY) as one other stock that is "treading water" but in a different manner than tech. EliLilly could potentially see $150 to $200 more in this stock coming up, Schneider ...